[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527892":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":22,"responsibleParty":85,"collaborators":7,"id":87,"slug":7,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":7,"enrollmentInfo":96,"targetDuration":7,"studyType":99,"phases":7,"briefSummary":100,"conditions":101,"keywords":7,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Merit Medical Systems, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Bearing nsPVA","Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Molly Ryan","CONTACT","314-620-7095","molly.ryan@merit.com",{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},"Vicky Brunk","vicky.brunk@merit.com",[23,36,54,69],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":7},"Astra Vascular\u002FAstra Vein Treatment Center","ACTIVE_NOT_RECRUITING","Brooklyn","New York","11234","United States",{"type":31,"coordinates":32},"Point",[33,34],-73.94958,40.6501,{"lat":34,"lon":33},{"facility":37,"status":38,"city":39,"state":7,"zip":7,"country":40,"cosmosGeoPoint":41,"geoPoint":45,"contacts":46},"The Wesley Hospital","RECRUITING","Brisbane","Australia",{"type":31,"coordinates":42},[43,44],153.02809,-27.46794,{"lat":44,"lon":43},[47,51],{"name":48,"role":16,"phone":49,"phoneExt":7,"email":50},"Sepinoud Firouzmand","0733719588","sepinoud.firouzmand@i-med.com.au",{"name":52,"role":53,"phone":7,"phoneExt":7,"email":7},"Nigel Mott, MD","PRINCIPAL_INVESTIGATOR",{"facility":55,"status":38,"city":56,"state":7,"zip":7,"country":40,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Alfred Health","Sydney",{"type":31,"coordinates":58},[59,60],151.20732,-33.86785,{"lat":60,"lon":59},[63,67],{"name":64,"role":16,"phone":65,"phoneExt":7,"email":66},"Adil Zia","61414063499","a.zia@alfred.org.au",{"name":68,"role":53,"phone":7,"phoneExt":7,"email":7},"Warren Clements, MD",{"facility":70,"status":38,"city":71,"state":7,"zip":7,"country":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Royal Gwent Hospital (Aneurin Bevan UHB)","Newport","United Kingdom",{"type":31,"coordinates":74},[75,76],-2.99835,51.58774,{"lat":76,"lon":75},[79,83],{"name":80,"role":16,"phone":81,"phoneExt":7,"email":82},"Judith Omang","01633 238084","Judith.Omang2@wales.nhs.uk",{"name":84,"role":53,"phone":7,"phoneExt":7,"email":7},"Nimit Goyal, MD",{"type":86,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100527892",false,"NCT06153667","Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)","Prospective, Multi-Center Study Using Bearing nsPVA Embolization Particles for the Treatment of uTErine fibRoids With Uterine Artery Embolization","BETTER-UAE","Inclusion Criteria:\n\n* Adult women ≥ 18 years old at the time of enrollment.\n* Subject has symptomatic uterine fibroid(s), suitable to embolization.\n* Subject provides written informed consent.\n\nExclusion Criteria:\n\n* Subject is pregnant.\n* Subject has suspected pelvic inflammatory disease or any other pelvic infection.\n* Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).","FEMALE","18 Years",{"count":97,"type":98},100,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.",[102],"Uterine Fibroid","2026-05-28",{"date":105,"type":106},"2026-05-29","ACTUAL",{"date":108,"type":106},"2024-08-22",{"date":110,"type":98},"2026-12",{"name":5,"class":6},4]